Sifilize Bağlı Bilateral Posterior Üveit
PDF

EDITÖRE MEKTUP

Sifilize Bağlı Bilateral Posterior Üveit

Mediterr J Infect Microb Antimicrob 2018;7:16-16 DOI: 10.4274/mjima.2018.16
, , , ,
PDF
İzin

Kaynakça

1

Rodriguez A, Calonge M, Pedroza-Seres M, Akova YA, Messmer EM, D'Amico DJ, Foster CS. Referral patterns of uveitis in a tertiary eye care center. Arch Ophthalmol. 1996;114:593-9.

2

Benson CE, Soliman MK, Knezevic A, Xu DD, Nguyen QD, Do DV. Bilateral papillitis and unilateral focal chorioretinitis as the presenting features of syphilis. J Ophthalmic Inflamm Infect. 2015;5:16.

3

Spoor TC, Ramocki JM, Nesi FA, Sorscher M. Ocular syphilis 1986. Prevalence of FTA-ABS reactivity and cerebrospinal fluid findings. J Clin Neuroophthalmol. 1987;7:191-5.

4

Dai T, Wu X, Zhou S, Wang Q, Li D. Clinical manifestations and cerebrospinal fluid status in ocular syphilis in HIV-Negative patients. BMC Infect Dis. 2016;16:245.

5

Amaratunge BC, Camuglia JE, Hall AJ. Syphilitic uveitis: a review of clinical manifestations and treatment outcomes of syphilitic uveitis in human immunodeficiency virus-positive and negative patients. Clin Exp Ophthalmol. 2010;38:68-74.

6

Clinical Advisory: Ocular Syphilis in the United States. 2015. Last accessed date: 01.03.2018 Available from: http://.www.cdc.gov/std/ syphilis/clinicaladvisoryos2015.htm

7

Akincioglu D, Özgönül C, Gökçe G, Durukan AH. A Case of Acute Bilateral Syphilitic Uveitis. Turk J Ophthalmol. 2015;45:122-4.

8

Altın A, Çınar P, Fırıcıoğulları E, Zorlu F. An ocular syphilis case with uveitis and multifocal chorioretinitis. Turkiye Klinikleri J Ophthalmol. 2008;17:57-61.

9

Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance, 2014. Atlanta: US Department of Health and Human Sciences; 2015.

10

Moradi A, Salek S, Daniel E, Gangaputra S, Ostheimer TA, Burkholder BM, Leung TG, Butler NJ, Dunn JP, Thorne JE. Clinical features and incidence rates of ocular complications in patients with ocular syphilis. Am J Ophthalmol. 2015;159:334-43.